Kroeger Christopher A.

MapLight CEO Kroeger sells 118,235 shares for $3.2M under 10b5-1 plan; stock down 20.4% from 52-week high

Christopher A. Kroeger, CEO of MapLight Therapeutics, executed two separate sales on 2026-05-18 totaling 118,235 shares for $3,214,999.73, reducing his holdings to 1,394,094 shares (a -7.8% reduction). The transaction was executed under a 10b5-1 trading plan adopted on 2025-12-29, meaning the sales were scheduled and non-discretionary. The stock currently trades at $26.50, down 20.4% from its 52-week high of $33.28 and down 11.8% over the past 30 days, though it has appreciated 53.6% over the past 90 days. The company reported a net loss of $60,668,000.00 for its most recent full fiscal year. While the CEO retained 1,394,094 shares post-transaction, the scheduled nature of the 10b5-1 sales means timing considerations do not apply to this filing.

CEO Christopher Kroeger sells nearly 68,500 shares for ~$1.95M across three days as stock rises from depressed levels.

Christopher Kroeger, MapLight's CEO, executed a substantial liquidation of approximately 68,500 shares over three days in early May, totaling nearly $1.95 million. The stock has rebounded sharply from deeply depressed levels over the prior quarter, and Kroeger's sales occurred well above what appear to be support levels established during the recovery. However, his prior two sales at this company were poorly timed—the stock rose after both exits—raising questions about whether his current sales represent genuine conviction about overvaluation or simply represent a large liquidation that happens to occur during a strong price period. MapLight remains unprofitable with significant quarterly losses, so the company's fundamentals have not improved materially. This is Kroeger's third consecutive filing consisting of sales, with no open-market purchases during his tenure as CEO, suggesting a consistent pattern of exiting rather than adding to his position.

CEO Christopher Kroeger sells ~50K shares across 8 transactions totaling $1.41M; fourth consecutive sale in 36 months amid mixed timing history.

Christopher Kroeger, MapLight's CEO, disposed of approximately 50,000 shares in eight separate transactions over three trading days, generating $1.41M in proceeds. This represents his fourth through eleventh open-market sales in the past 36 months—a sustained pattern of dispositions rather than an isolated event. Critically, his prior two evaluable sales at this stock were both poorly timed: the stock rose after each exit, meaning Kroeger was selling into weakness rather than ahead of declines. The company itself is loss-making with significant quarterly cash burn, so the timing misses on his prior sales are particularly noteworthy—the stock recovered despite deteriorating fundamentals. The shares were sold at prices ranging from the low-to-mid $27 range through the high $20s, while the stock now trades around $30 per share, approaching its 52-week highs after a strong recent run. Kroeger's repeated selling despite poor prior timing and the company's unprofitable state suggests either structural liquidity needs or a disconnect between his exit decisions and subsequent market performance.

MPLT CEO Kroeger sold 19,187 shares over 2 days at $26.93–$27.49 for $521,146.07 total; retains 1,630,564 shares.

CEO Christopher A. Kroeger executed 3 separate sales totaling 19,187 shares for $521,146.07 on April 15–16, 2026, at prices ranging from $26.93 to $27.49. Despite the sales, Kroeger retained 1,630,564 shares post-transaction, representing only a 1.2% reduction in his prior holdings. The current stock price of $30.05 reflects a 76.6% gain over 30 days and sits at the 52-week high, whereas the transaction prices were $26.93–$27.49—more than 2 dollars below current levels. MapLight Therapeutics reported negative net income of $-29,418,000.00 for its most recent full fiscal year, placing the company in a loss position despite its $1.3B market capitalization. The modest scale of the sale relative to continued substantial holdings offers limited insight into directional conviction.